Test Price
2,800 AEDโ Home Collection Available
๐ Results in 3โ4 weeks
UBQLN2 Gene Analysis (Amyotrophic Lateral Sclerosis, X-Linked Juvenile & Adult-Onset) Genetic Test in UAE | 2800 AED | DHA Licensed Facility
Executive Summary & Core Metrics
Executive Overview
- Diagnostic Accuracy: 99.9% analytic sensitivity and specificity via ISO-accredited sequencing with orthogonal Sanger confirmation.
- Specimen Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
- Post-Test Support: Telephonic clinical guidance from a Consultant Medical Geneticist to interpret results and discuss familial implications.
- Insurance & Billing: Direct billing verification via WhatsApp +971 54 548 8731.
Price
2,800 AED
Turnaround Time
3โ4 Weeks
Specimen Type
Peripheral Whole Blood
DHA License
No. 1143
Test Overview & Methodology
The UBQLN2 gene test utilizes next-generation sequencing (NGS) with Sanger confirmation to detect pathogenic variants associated with X-linked juvenile and adult-onset amyotrophic lateral sclerosis (ALS). This molecular analysis targets coding exons and flanking intronic regions of the UBQLN2 gene to identify disease-causing mutations that impair ubiquitin-proteasome pathway function in motor neurons. Results assist neurologists and genetic counselors in confirming diagnosis, stratifying familial risk, and guiding reproductive planning. The assay is performed under ISO 9001:2015 quality management standards within a DHA-licensed laboratory facility.
| Feature | Our Test (DHA-Certified) | Alternative (Research-Only NGS) |
|---|---|---|
| Precision | 99.9% analytic sensitivity & specificity | Variable quality, no clinical validation |
| Method | NGS + Sanger confirmation, ISO 9001:2015 | NGS without orthogonal confirmation |
| Turnaround Time | 3โ4 weeks (guaranteed) | 6โ8 weeks, uncertain |
| Clinical Validity | Clinically validated with phenotype correlation | Research use only, not diagnostic |
Physician Insight & Safety Protocols
"A positive UBQLN2 mutation confirms the molecular basis of X-linked ALS; however, the result must be interpreted within the full clinical context including neurological exam findings, family pedigree, and disease progression trajectory. Mandatory pre-test and post-test genetic counseling ensures that patients and families understand the implications for prognosis, recurrence risk, and reproductive options." โ Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication & Clinical Advisory
Important Clinical Precautions
- Do not alter or discontinue any prescribed medications, including riluzole or other ALS therapies, without direct consultation with your treating neurologist.
- This genetic test is an adjunct to clinical diagnosis and does not replace comprehensive neurological evaluation or ongoing symptom management.
- Results may take 3โ4 weeks to finalize; continue all current treatments and monitoring during this period.
Exclusion Criteria & Emergency Red Flags
Safety Exclusion Criteria
- Inability to provide informed consent (minors require legal guardian consent per UAE Federal Law).
- Failure to complete mandatory pre-test genetic counseling session.
- Active acute respiratory distress, severe dysphagia, or rapidly progressive neuromuscular decline requires immediate emergency care before testing.
Patient FAQ & Clinical Guidance
1. What does the UBQLN2 gene test detect and why is it performed?
Answer: This test identifies pathogenic mutations in the UBQLN2 gene to confirm a clinical suspicion of X-linked amyotrophic lateral sclerosis (ALS). It is performed when a patient presents with progressive motor weakness, has a family history suggestive of X-linked inheritance, or requires definitive molecular diagnosis for prognosis and family risk assessment.
2. How is the sample collected and what is the turnaround time?
Answer: A certified phlebotomist collects a peripheral whole blood sample at your home via VIP Mobile Phlebotomy between 8 AM and 11 PM daily. Results are delivered within 3โ4 weeks from sample receipt at the DHA-licensed laboratory.
3. Is genetic counseling required before and after testing?
Answer: Yes. A mandatory pre-test genetic counseling session is conducted to draw a three-generation pedigree, explain inheritance patterns, and obtain fully informed consent. Post-test counseling is also provided to discuss results, recurrence risks, and reproductive options in accordance with UAE healthcare regulations.
4. What does a positive or negative result mean for my family?
Answer: A positive result confirms the genetic basis of ALS and indicates that first-degree relatives may be at risk and should consider predictive testing after counseling. A negative result reduces but does not entirely exclude a genetic cause, as other genes may be involved. Genetic counselors will guide family testing decisions.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance Framework
- Data Protection: All genetic and personal data are processed in strict compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL), ensuring encrypted storage, controlled access, and patient consent management.
- Health Information Governance: Laboratory operations adhere to Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, governing the secure handling of electronic health records and diagnostic data.
- DHA Licensing: The laboratory operates under DHA Facility License Number 1143, located at Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE, with routine inspections and quality audits.
- Patient Rights: All testing is conducted under the principles of informed consent and medical liability protections as outlined in Federal Decree-Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Test Name | UBQLN2 Gene Analysis (Amyotrophic Lateral Sclerosis, X-Linked Juvenile & Adult-Onset) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3โ4 weeks (21โ28 calendar days) |
| Sample Type / Matrix | Peripheral Whole Blood (VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily 8 AM โ 11 PM) |
| Methodology Used | Next-Generation Sequencing (NGS) with Sanger Confirmation, ISO 9001:2015 |
| ICD-10-CM Code | G12.21 (Amyotrophic lateral sclerosis) |
| LOINC Code | 81265-2 (UBQLN2 gene mutation analysis in Blood or Tissue by Sequencing) |
| DHA Facility License & Laboratory Address | DHA License No. 1143 โ Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
Preparation Required
[]
Medically Reviewed by Dr. Lina Osama Zaki Quteineh
All content reviewed by qualified professionals for accuracy.
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians